CHANG LIU

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have been used to treat non-small cell lung carcinoma (NSCLC) patients that have EGFR-activating mutations. EGFR-TKI monotherapy in most NSCLC patients with EGFR mutations who initially respond to EGFR-TKIs results in the development of acquired resistance. We investigated the(More)
The aim of the present study was to evaluate the safety and efficacy of administering cytokine‑induced killer cells (termed allogeneic CIKs), obtained from the blood of the offspring of patients, for the treatment of non‑small cell lung cancer. Symptoms, signs and laboratory assessment results for 303 cancer patients were collected prior to and following(More)
This study investigated the plasma levels of tumor necrosis factor α (TNF-α) and the expression levels of TNF receptors (TNFRs) in patients with multiple trauma, together with the association between the levels of this cytokine and these cytokine receptors with the severity of traumatic injury. Blood samples were obtained from 60 multiple trauma patients at(More)
  • 1